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with Glatiramer Acetate
Spencer Moore,1 Anna J. Khalaj,1 Rhusheet Patel,1 JaeHee Yoon,1 Daniel Ichwan,1
Liat Hayardeny,2 and Seema K. Tiwari-Woodruff1,3*
1Department of Neurology, UCLA School of Medicine, Los Angeles, California
2Pharmacology Unit, Global Innovative Research and Development, Teva Pharmaceutical Industries,
Netanya, Israel
3Brain Research Institute, UCLA School of Medicine, Los Angeles, California
Glatiramer acetate (GA; Copaxone) is an approved drug
for the treatment of multiple sclerosis (MS). The underlying
multifactorial anti-inflammatory, neuroprotective effect of
GA is in the induction of reactive Tcells that release immu-
nomodulatory cytokines and neurotrophic factors at the
injury site. These GA-induced cytokines and growth fac-
tors may have a direct effect on axon function. Building on
previous findings that suggest a neuroprotective effect of
GA, we assessed the therapeutic effects of GA on brain
and spinal cord pathology and functional correlates using
the chronic experimental autoimmune encephalomyelitis
(EAE) mouse model of MS. Therapeutic regimens were uti-
lized based on promising prophylactic efficacy. More spe-
cifically, C57BL/6 mice were treated with 2 mg/mouse/day
GA for 8 days beginning at various time points after EAE
post-induction day 15, yielding a thorough, clinically rele-
vant assessment of GA efficacy within the context of
severe progressive disease. Therapeutic treatment with
GA significantly decreased clinical scores and improved
rotorod motor performance in EAE mice. These functional
improvements were supported by an increase in myelin-
ated axons and fewer amyloid precursor protein-positive
axons in the spinal cords of GA-treated EAE mice. Further-
more, therapeutic GA decreased microglia/macrophage
and T cell infiltrates and increased oligodendrocyte num-
bers in both the spinal cord and corpus callosum of EAE
mice. Finally, GA improved callosal axon conduction and
nodal protein organization in EAE. Our results demonstrate
that therapeutic GA treatment has significant beneficial
effects in a chronic mouse model of MS, in which its posi-
tive effects on both myelinated and non-myelinated axons
results in improved axon function. VC 2014 Wiley Periodicals,
Inc.
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Multiple sclerosis (MS) is a chronic inflammatory,
demyelinating disease of the central nervous system
(CNS) that leads to axon damage and resultant motor,
sensory, and cognitive deficits. Although research is
ongoing to elucidate the precise cellular steps that lead to
this axon damage, evidence suggests that an autoimmune
response mediated by the adaptive immune system con-
tributes to the formation of demyelinated plaques in white
matter and subsequent axon damage (Vollmer et al.,
2002; Weissert, 2013). MS relapse and associated manifes-
tations of dysarthria, ataxia, and tremors may result from
accumulated axon damage during demyelinating inflam-
matory insults (Weissert, 2013). Recent evidence indi-
cates that gray matter pathology in MS patients, which
includes demyelination and activated microglia, contrib-
utes to cognitive defects (Bo et al., 2003; Morgen et al.,
2006; Niepel et al., 2006). Therefore, it is of great thera-
peutic interest to characterize disease-modifying agents
capable of limiting or reversing the axon damage that
contributes to disease burden. The murine model of MS
experimental autoimmune encephalomyelitis (EAE) reca-
pitulates the inflammatory, demyelinating lesions of white
and gray matter in cortex, corpus callosum (CC), and spi-
nal cord observed in MS patients (Mangiardi et al., 2011).
Indeed, axon damage and transection in murine EAE cor-
relate strongly with clinical disease severity (Kornek and
Lassmann, 2003).
Glatiramer acetate (GA; Copaxone) is an FDA-
approved agent for first-line treatment of MS that signifi-
cantly reduces relapse rates in relapse-remitting (RR) MS
patients (Johnson et al., 2001), reduces the risk of devel-
oping clinically definite MS in patients with clinically
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isolated syndrome (Comi et al., 2009), and suppresses
EAE in animal models (Arnon and Sela, 2003). GA, a
synthetic analogue of myelin basic protein (MBP), is a
random polypeptide composed of the amino acids
L-glutamic acid, L-lysine, L-alanine, and L-tyrosine, and
its mechanism of action in MS may lie in preferential dif-
ferentiation of Treg and Th2 helper cells (Duda et al.,
2000; Weber et al., 2007), a Th1 to Th2 shift, and upreg-
ulation of anti-inflammatory cytokines (Schrempf and
Ziemssen, 2007). GA does not cross the blood–brain bar-
rier but acts on the CNS by inducing peripheral Th2 cells
that migrate to the CNS by binding to major histocom-
patability complex class II molecules present on MBP-
recognizing antigen presenting cells (APC; for review see
Scott, 2013). These bind to receptors on GA-reactive
T cells, triggering cytokine production (Scott, 2013).
Recently, decreased activation of CNS tissue-damaging
microglia was demonstrated in GA-treated MS patients
(Ratchford et al., 2012). EAE studies have shown that
GA modulates the immune response by increasing pro-
duction of IL-10 (Begum-Haque et al., 2013) and Treg
cells and reducing Th17 cells (Aharoni et al., 2010).
Indeed, GA administration at early and late EAE time
points significantly reduced clinical disease (Aharoni et al.,
2005). Other GA EAE studies have demonstrated pre-
served axonal integrity in the spinal cord (Gilgun-Sherki
et al., 2003) and enhanced neurogenesis and neuroprotec-
tion in the hippocampus, cerebellum, and subventricular
zones (Aharoni et al., 2005). However, less is known
about the effects of GA on MS/EAE CC pathology and
its functional correlates. It is well known that CC integ-
rity in MS is compromised by demyelinating lesions, dif-
fuse tissue damage, and abnormalities in neural
connectivity, making it a useful surrogate marker of clini-
cally significant brain abnormalities (Boroojerdi et al.,
1998; Warlop et al., 2008; Ozturk et al., 2010).
In this study, we investigated the functional effects of
GA treatment during EAE along with neural and inflam-
matory substrates in spinal cord and CC. Specifically, we
sought to determine whether GA treatment during
chronic EAE preserves myelination and structural and
functional integrity of CNS axons. We hypothesized that
GA-induced improvement in clinical outcomes of motor
coordination in EAE mice would have neuronal correlates
with increased axon myelination, structural integrity, and
conduction. To examine this, we induced chronic EAE in
adult C57BL/6 mice expressing enhanced green fluores-
cent protein on the proteolipid protein promoter
(PLP_EGFP) and treated them daily with GA for 8 days at
various time points during EAE. We report here that ther-
apeutic (i.e., initiated after the presentation of clinical dis-
ease) GA treatment during chronic EAE reduced clinical
disease and improved motor performance. Spinal cords of
GA-treated EAE animals showed increased myelination
and axonal integrity as well as decreased inflammatory
infiltration. Electrophysiologically a functional improve-
ment in CC axon conduction correlated with increased
myelination, pro-myelinating cellularity, and preserved
nodal architecture. In sum, these findings indicate a prom-
inent functional improvement in EAE mice as a result of
therapeutic GA treatment consistent with improved axo-
nal integrity and myelination of CNS neurons.
MATERIALS AND METHODS
Animals
Breeding pairs of PLP_EGFP mice on the C57BL/6
background were a kind gift from Dr. Wendy Macklin (Uni-
versity of Colorado, Denver; Mallon et al., 2002). Mice were
bred in-house at the University of California, Los Angeles
(UCLA) animal facility. All procedures were conducted in
accordance with the National Institutes of Health and approved
by the Animal Care and Use Committee of the Institutional
Guide for the Care and Use of Laboratory Animals at UCLA.
GA
GA consists of acetate salts of synthetic polypeptides con-
taining four amino acids: L-alanine, L-glutamate, L-lysine, and
L-tyrosine (Teitelbaum et al., 1971). GA (average molecular
weight of 7,700 kDa) was obtained from Teva Pharmaceutical
Industries (Petah Tiqva, Israel). GA was administered daily for
8 consecutive days by subcutaneous (s.c.) injection (2 mg/
mouse, in phosphate buffered saline [PBS]) therapeutically,
beginning after the appearance of clinical disease (EAE post-
induction day 15 onward).
EAE
Active EAE was induced in 8 week-old sex-matched
PLP_EGFP C57BL/6 mice (Tiwari-Woodruff et al., 2007;
Crawford et al., 2010; Mangiardi et al., 2011). Specifically,
active EAE was induced by immunization with 200 lg of mye-
lin oligodendrocyte glycoprotein (MOG; amino acids 35–55)
in combination with Mycobacterium tuberculosis in complete
Freund’s adjuvant on post-immunization days 0 and 7. Addi-
tionally, mice were injected with pertussis toxin (500 ng/
mouse) on days 0 and 2. Normal animals were administered all
but MOG. Mice were monitored and scored daily for clinical
disease severity according to the standard EAE grading scale: 0,
unaffected; 1, tail limpness; 2, failure to right upon an attempt
to roll over; 3, partial hind limb paralysis; 4, complete hind
limb paralysis; and 5, moribund. Within each treatment group,
the mean clinical score was determined daily, thereby yielding
the mean clinical score for that treatment group. Mice were fol-
lowed clinically for up to 40 days after disease induction.
Rotorod Motor Performance
Motor performance was tested up to two times per week
for each mouse by using a rotorod apparatus (Med Associates,
St. Albans, VT; Kumar et al., 2013; Moore et al., 2013).
Briefly, animals were placed on a rotating horizontal cylinder
for a maximum of 200 sec. The amount of time the mouse
remained walking on the cylinder without falling was recorded.
Each mouse was tested at speeds of 3–30 rpm and given three
trials on any given day. The three trials were averaged to report
a single value for an individual mouse, and averages were then
calculated for all animals within a given treatment group. The
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first two trial days prior to the start of immunization (day 0)
served as training trials.
Immunohistochemistry
Formalin-fixed coronal brain sections containing
midline-crossing CC above lateral ventricles or dorsal hippo-
campus were examined by immunohistochemistry using various
series of cell type-specific antibodies, as previously described
(Tiwari-Woodruff et al., 2007). The following antibodies were
used to detect axons: anti-neurofilament 200 kDa (NF200;
1:500; Millipore, Bedford, MA; and 1:1;000; Sigma, St. Louis,
MO); astrocytes: anti-glial fibrillary acidic protein (GFAP;
1:1,000; Millipore); oligodendrocyte (OL) lineage cells: anti-
oligodendrocyte transcription factor 2 (olig2; 1:500; Millipore);
mature OLs: anti-CC1 (1:1,000; GeneTex) and PLP_EGFP
fluorescence; myelin: anti-MBP (1:1;000, Millipore); T cells:
anti-CD3 (1:1,000; Abcam, Cambridge, MA; and Millipore);
and microglia/macrophage/monocyte: leukocyte antigen
marker anti-CD45 (1:500; PharMingen, La Jolla, CA) and amy-
loid precursor protein (APP; 1:1,000; Abcam and Millipore).
The fluorescently tagged secondary antibody step was per-
formed by labeling with antibodies conjugated to TRITC,
FITC, or Cy5 (Vector, Burlingame, CA; Chemicon, Teme-
cula, CA). IgG control experiments were performed for all pri-
mary antibodies, and no staining was observed under these
conditions. To assess cell numbers, nuclear stain 40,6-diami-
dino-2-phenylindole (DAPI; 2 ng/ml; Molecular Probes,
Eugene, OR) was added for 15 min post-secondary antibody
addition and prior to final washes. Sections were mounted on
slides, allowed to dry, and coverslipped in Fluoromont G
(Fisher Scientific, Pittsburgh, PA).
Microscopy and Quantification
Immunostaining was quantified using unbiased stereology.
The dorsal column (DC) was delineated (Fig. 3A) using the
drawing tool in ImageJ version 1.29 (Windows version of NIH
Image; http://rsb.info/nih/gov/ij), and MBP, GFAP, CD3, and
CD45 staining intensity was quantified within this region.
NF2001 and MBP1 axons were counted in the ventral column
(VC) of thoracic spinal cord (Fig. 3A). All images (RGB) were
converted to gray scale, split, and separated by color channel in
ImageJ. To avoid experimenter bias, autoadjustment of bright-
ness, contrast, and threshold of staining signal were carried out
in NIH software. A grid plug-in (ImageJ) was used for counting
points per area of interest. Adenomatus polyposis coli (CC1)1
mature OLs, olig21 OL lineage cells, and CD31 T cells within
the CC or spinal cord dorsal column were counted manually
using 310 or 340 magnification images and compared blindly
among normal, vehicle-treated EAE, and GA-treated EAE
groups. Inflammatory cells were quantified by counting the
number of CD451 and CD31 cells with DAPI1 nuclei in
delineated thoracic spinal cord dorsal column (and/or delineated
CC). Myelin (MBP1) and astrocytes (GFAP1) were calculated
as percentage area intensity within the spinal cord dorsal column
(Fig. 3) and delineated CC. Spinal cord axonal densities were
calculated by counting the number of NF2001 cells in a 340
image of ventral column of thoracic spinal cords, where coher-
ent and similar diameter axons are present. Myelinated axon
densities were calculated by counting axons (NF2001) with a
clear ring of MBP1 myelin staining around them. Damaged
axons were calculated by counting APP1 axons.
Electrophysiological Recording
Brain slices (400 lm thick) corresponding approximately
to plates 40–48 in the atlas of Franklin and Paxinos (2001) were
used for electrophysiology recording, as previously described
(Crawford et al., 2010). Compound action potential (CAP)
recordings were performed as previously described (Crawford
et al., 2009a,b). Stimulation used for evoked CAP was
constant-current stimulus-isolated square wave pulses.
Statistical Analysis
Quantification of immunostaining results was similar to
that in previous studies (Tiwari-Woodruff et al., 2007; Craw-
ford et al., 2009b). Specifically, we used two sections (about
400 lm apart)/mouse from electrophysiology-recorded brains
and two sections/mouse from formalin-perfused brains. Among
the n5 8 mice per treatment group, four mice were used for
electrophysiology and four were formalin perfused, resulting in
a total of 16 sections per treatment group for immunostaining.
To quantify electrophysiology results from each treatment
group, recordings from two caudal slices of four animals per
two experiments resulted in a total of 16 analyzed recordings.
Values are expressed as mean6 SEM. Statistical analysis of
mean values was carried out using one-way analysis of variance
(ANOVA) and Friedman test (for clinical scores only) or Bon-
ferroni’s multiple-comparisons post-test. Differences were con-
sidered significant at P< 0.05. Statistical analyses were
performed in MicroCal Origin (Northampton, MA) or Prism 4
(GraphPad Software, La Jolla, CA).
RESULTS
Therapeutic Treatment with 2 mg GA for 8 Days,
Initiated After Onset of Clinical Disease,
Attenuates EAE Clinical Scores
Given the chronic progressive, inflammatory, and
demyelinating nature of MOG35–55-induced active EAE
in C57BL/6 mice, we hypothesized that a clinically
detectable response to GA treatment would be dependent
on therapy-initiation timing. To test this hypothesis, we
induced active EAE in adult C57BL/6 female mice and
tested treatment responses at two time points. Clinical
EAE scores were recorded daily by an observer blind to
the treatment groups. EAE was clinically evident by post-
induction days 12–15, accelerated in progression,
peaked by days 16–21, and subsequently assumed a
chronic phase. We identified days 16 (EAE onset) or 21
(peak EAE) as initial time points for an 8 day GA treat-
ment regimen to determine if disease stage causes a differ-
ential treatment response and the optimal window of time
for therapy. Mice were randomized to receive daily injec-
tions of vehicle (PBS) or 2 mg/mouse GA starting on day
16, when the mean EAE score was 2 (hindlimb weak-
ness; Fig. 1A), or day 21, when the mean EAE score was
3 (partial hindlimb paralysis; Fig. 1B), and followed
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until day 40. Vehicle-treated mice assumed chronic,
persistent EAE disability phenotype beginning at day
20, as indicated by increased EAE scores. GA treatment
initiated at day 16 resulted in suppression of disease phe-
notype, with treated mice showing a dramatic and persis-
tent reduction in clinical disease burden (Fig. 1A). When
GA treatment was initiated at the later time point (day
21), a significant (albeit less dramatic) and persistent
decrease in clinical disease burden was observed (Fig. 1B).
These results demonstrate the time-dependent efficacy of
therapeutic GA treatment, and the persistence of clinical
benefit long after cessation of treatment indicates a dura-
ble response.
Therapeutic Treatment with GA Improves Motor
Performance in EAE Mice
To determine whether therapeutic GA-induced
improvements in EAE clinical scores were functionally
relevant, EAE mice were tested for rotorod motor per-
formance. This behavioral assay of motor coordination
and balance in rodents has strong translational correlates
with motor assessments of the Kurtzke Expanded Disabil-
ity Status Scale (EDSS) in MS patients. More specifically,
mice are tested for their ability to remain on a rotating
cylinder for a maximum of 200 sec per trial, with three
trials per day. Although normal, healthy mice remain on
the cylinder for the duration of the trial period, clinically
severe EAE mice fall off the apparatus much earlier, indi-
cating functional motor disability. Mice were trained on
the task prior to EAE induction. Chronic EAE was
induced in adult female (Fig. 2A,B) and male (Fig. 2C,D)
C57BL/6 mice, as previously described, with a daily 8-
day treatment regimen beginning on EAE post-induction
day 15 (females) or 18 (males), and mice were sacrificed at
day 40 or 36, respectively. For each experiment, GA ther-
apy was initiated when the mean clinical EAE score
reached 3 (partial hind limb paralysis) to probe the abil-
ity of GA both to prevent disease progression and pro-
mote motor recovery from severe disease. Mice were
randomized to receive either vehicle or GA treatment.
EAE clinical scores were obtained daily throughout the
experiment by an observer blind to treatment conditions
(Fig. 2A,C). Mice were tested on the rotorod several
times throughout the disease course. As was observed in
earlier experiments, GA treatment significantly suppressed
EAE clinical disease in these two experiments, whereas
vehicle-treated mice displayed severe and chronic disabil-
ity beginning at day 15 (Fig. 2A,C). Rotorod motor
performance declined sharply as EAE clinical disability
progressed, but GA treatment rescued performance on
the task such that GA-treated mice approached normal
performance within 10 days of treatment initiation (Fig.
2B,D). No difference in response to GA treatment, as
measured by clinical disease severity and rotorod perform-
ance, was observed between males and females. These
results reveal that therapeutic GA imparts significant func-
tional motor improvement in clinically severe EAE mice.
Improvement in Motor Performance with
Therapeutic GA Correlates with Reduced
Inflammation in Spinal Cords of EAE Mice
Spinal cords of EAE mice reliably show pathological
inflammatory lesions and sites of demyelination that contrib-
ute to clinical and motor deficits (Mangiardi et al., 2011). To
characterize the effects of GA treatment on spinal cord
pathology, EAE mice from the Figure 1B experiment, in
which treatment was initiated at day 21 (i.e., when demye-
lination and axonal damage are expected to be more pro-
nounced and challenging to remedy), were sacrificed and
formalin-perfused to obtain thoracic spinal cord sections for
Fig. 1. Therapeutic treatment with 2 mg GA for 8 days after onset of
clinical EAE attenuates clinical disease scores. PLP_EGFP female mice
were administered 2 mg/mouse/day GA (squares) or PBS (vehicle;
circles) by s.c. injection on days 16–23 (A) or days 21–28 (B) after ini-
tiation of active EAE. Mice were scored using the standard EAE grad-
ing scale. EAE scores of mice treated with GA beginning at mid-EAE
(day 16) showed significant improvement throughout the duration of
disease, whereas EAE mice treated with GA beginning at peak EAE
(day 21) showed significant improvement after 8 days of continuous
treatment, compared with vehicle-treated EAE mice. Normal mice
showed no disease; their clinical scores remained 0 throughout the
experiment. Number of mice per treatment group for each experiment:
normal, n5 8; EAE1 vehicle, n5 8 and 10; post EAE1GA, n5 10
and 15. Data are representative of experiments repeated three times.
**P< 0.001, ANOVA, Friedman test. [Color figure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
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immunohistochemistry. Inflammation resulting from infiltra-
tion by immune cells and astrogliosis are hallmarks of EAE
spinal cord pathology. PLP_EGFP1 loss and increased
DAPI1 (which includes inflammatory infiltrates) infiltration
observed in the dorsal column of vehicle-treated EAE spinal
cord (Fig. 3A, center) were decreased by day 21-initiated
GA treatment (Fig. 3A, right). A major infiltrating cell popu-
lation consisted of CD31 T cells in vehicle-treated EAE spi-
nal cords, as previously observed (Fig. 3B; Mangiardi et al.,
2011). T cell numbers, however, were significantly decreased
in the spinal cord dorsal column of GA-treated EAE mice
(Fig. 3B,C). Activation of resident CD451 CNS microglia is
a consistent marker of EAE lesions, and here we report a
reduction of CD451 CNS microglia in GA-treated EAE
spinal cord dorsal column (Fig. 3F,G). Additionally, astro-
gliosis is observed in EAE lesions (Voskuhl et al., 2009). We
observed GFAP1 astrogliosis in both EAE conditions, with a
nonsignificant trend toward reduction in the GA-treated
group (Fig. 3D,E). Altogether, these results suggest an
immunomodulatory effect of GA not on astrocytes but on
cells from the hematopoietic line (i.e., T cells and microglia).
Improvement in Motor Performance with
Therapeutic GA Initiated During Late EAE is
Associated with Improved Axon Myelination,
Improved Axon Numbers, and Reduced Axon
Damage
Inflammatory demyelination and axon damage
are mainly responsible for the axon dysfunction that
Fig. 2. Therapeutic GA decreases EAE-induced motor deficit as meas-
ured by rotorod motor performance. PLP_EGFP C57BL/6 female mice
were given GA (blue) for 8 days when the average EAE score was 3,
beginning on EAE post-induction day 15, when the average EAE score
was 3 (A). In a separate experiment, male mice were given GA (blue)
for 8 days when the average EAE score was also 3, beginning on day
18 (C). Each experiment contained a group of sex-matched EAE mice
administered PBS (vehicle, red). Mice were scored using the standard
EAE grading scale. EAE scores of GA-treated mice showed significant
improvement throughout the duration of disease compared with
vehicle-treated EAE mice. Normal mice (black) did not show disease
and their clinical scores remained 0 throughout the experiment.
**P< 0.001, ANOVA, Friedman test; n5 10 mice/group. To assess
the clinical significance of GA treatment during EAE, mice from experi-
ments in A and C were subjected to a rotorod motor performance test
frequently used to assess spinal cord injury. Vehicle-treated EAE mice
(red) demonstrated an abrupt and consistent decrease in time (sec) that
they were able to remain on the rotorod beginning at day 15 after dis-
ease induction, and this disability persisted throughout the observation
period. When a group of EAE mice began GA treatment (blue) on day
15 (B) or 18 (D), disability continued but was less severe. However,
from days 30–40 the GA-treated EAE group exhibited significant recov-
ery. ** P< 0.05, ANOVA; n5 10 mice/group. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Fig. 3. Therapeutic GA reduces inflammation in spinal cords of EAE
mice. Representative PLP_EGFP (green) thoracic spinal cord sections
costained with DAPI (red) from normal, EAE1 vehicle and EAE1GA
groups described in Figure 1B, with treatment initiated on peak EAE
day 21 (A; 34 magnification). All animals were sacrificed at EAE post-
induction day 40. White-dashed perimeters (DC, dorsal column) and
boxes (VC, ventral column) denote regions of the spinal cord used for
quantification. No inflammatory nuclei are observed in normal controls,
whereas vehicle-treated EAE spinal cord shows multifocal to coalescing
infiltrates in the leptomeninges. Treatment with 2 mg/day GA for 8
days resulted in fewer DAPI1 cell infiltrates in the lateral funiculus (LF),
DC, and VC*. Consecutive PLP_EGFP (green) thoracic spinal cord sec-
tions co-immunostained for CD3 (B, red, 310), GFAP (D, red, 340),
or CD45 (F, red, 340) are shown from partial images (dashed boxes in
B) of normal control, vehicle-treated EAE, and GA-treated EAE mice.
Vehicle-treated EAE spinal cords had large areas of CD451 and GFAP1
cell staining in the DC compared with normal controls, whereas GA-
treated EAE mice showed a significant decrease in CD3 and CD45 pos-
itivity. Number of CD31 (C), GFAP1 (E), and CD451 (G) cells per
400 mm2 or cell intensity within the DC were quantified. Compared
with normal controls, treatment with GA induced a decrease in CD31
and CD451 cell numbers, but not GFAP1 immunoreactivity. Data are
representative of experiments repeated in their entirety on another set of
EAE mice. *P< 0.05, **P< 0.001, 1 3 4 ANOVA; n5 6–8 mice/
group. [Color figure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]
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manifests as clinical and motor deficits in EAE. Axon
damage may occur independently or secondarily to
demyelination. Thus, the decrease in motor deficits
observed in GA-treated EAE mice may be due to a
direct or indirect effect of GA on spinal cord axon mye-
lination and axon health. MBP is a reliable marker of
CNS myelination. The spinal cord dorsal column, a
major myelinated ascending fiber tract, displayed a
decrease in MBP staining in vehicle-treated EAE animals
(Fig. 4A, center) compared with normal animals. In con-
trast, the spinal cord dorsal column of GA-treated EAE
mice showed improved MBP staining intensity (Fig. 4A,
right; Fig. 4B). To explore whether this improvement is
attributable to inhibited demyelination and/or acceler-
ated remyelination, we further characterized this myeli-
nation effect. Mature myelin-producing OLs were
immunostained for CC1. Therapeutic GA induced an
increase in CC11 mature OL cell numbers (Fig. 4 C,D).
Analysis of all OL lineage cells, including OL progeni-
tors, using OL transcription factor 2 marker olig2
revealed a decrease in olig21 cells in vehicle-treated
EAE spinal cord dorsal column and a reversal of this
effect in GA-treated EAE spinal cord dorsal column.
Taken together, these findings point to reduced loss of
OL lineage cells. The myelin-increasing effects of GA
are likely to impact axon pathology positively, so they
may be functionally relevant.
To further characterize the effects of GA on axon
pathology, we examined the spinal cord ventral col-
umn of EAE mice. The pronounced axonal loss (as
measured by NF2001 stain) observed in vehicle-
treated EAE spinal cord was attenuated with GA treat-
ment (Fig. 5A,B). b-APP is known to accumulate in
damaged axons (Mangiardi et al., 2011). GA treatment
resulted in fewer b-APP1 axons compared with
vehicle-treated EAE spinal cord ventral column (Fig.
5C,D). Consistent with observed incomplete recovery
from clinical signs of EAE, GA treatment partially pro-
tected against EAE-induced axonal loss and damage.
These findings point to a significant beneficial effect of
therapeutic GA in upholding CNS axon numbers and
integrity in EAE.
Fig. 4. Therapeutic GA restores myelin intensity and OL lineage cells in
spinal cords of EAE mice. At EAE post-immunization day 36 (Fig. 1B
experiment, in which treatment was initiated on day 21, at peak EAE)
vehicle-treated EAE mice had reduced myelin staining intensity (A,B;
MBP, red; 310) and decreased numbers of mature OLs (C,D; APC/
CC1, red; 340) and all OL lineage cells (E,F; Olig2, red; 340), com-
pared with normal controls, in the DC of thoracic spinal cord sections.
In contrast, GA-treated EAE mice showed significant improvement in
myelin staining intensity and number of OL cells (A-F). Myelin density
and OL numbers are presented as percentage of normal. *P< 0.05,
**P< 0.001, 1 3 4 ANOVA; n5 8 mice/group. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Therapeutic GA Decreases Lesion Load and
Increases PLP_EGFP Fluorescence in EAE Brain
Inflammatory demyelination of white matter tracts of
the optic nerve, spinal cord, and brain is a pathological hall-
mark of MS. Our group has demonstrated consistent
inflammatory demyelinated lesions in the CC and cortical
gray matter of chronic MOG35–55-induced EAE mice
(MacKenzie-Graham et al., 2009; Crawford et al., 2010b;
Mangiardi et al., 2011; Moore et al., 2013). The CC is the
major cerebral commissure and is commonly compromised
in MS, in which it frequently displays focal demyelinating
lesions and atrophy beginning at early disease stages (Bloom
and Hynd, 2005; Audoin et al., 2007). It is therefore
important to study how CC damage influences cognitive
impairment and physical disability in MS. In addition to
assessing GA treatment effects in the spinal cords of EAE
animals, we assessed GA effects in the CC of EAE mice.
The CC of vehicle-treated PLP_EGFP mice showed
reduced PLP_EGFP fluorescence intensity (Fig. 6A,C).
This decrease was attenuated with GA treatment (Fig. 6B).
Additionally, widespread inflammatory lesions observed in
the CC of vehicle-treated EAE mice (Fig. 6B,D; dashed
boxes and stars) were reduced with GA treatment. Repre-
sentative brain sections are from the Figure 1B experiment,
in which treatment was initiated at peak EAE (day 21).
Therapeutic GA Improves Callosal Axon
Conduction in EAE Mice
To assess the functional implications of and build
upon the mechanistic insight achieved by cellular and
structural assessments of GA-induced CNS improve-
ments, we measured callosal axon conduction in coronal
slices from vehicle-treated and therapeutic GA-treated
EAE animals (subjects from Fig. 1A experiment, in which
treatment was initiated on day 16). Our group has rou-
tinely studied axon conduction in brain slices by using an
electrophysiological assay to measure local field potential
change in response to stimulating a CAP in CC with a
square wave current pulse (Crawford et al., 2009b, Patel
et al., 2013). With respect to time, the typical CAP shows
two distinct voltage deflections: N1, predominantly from
large myelinated axons, and N2, predominantly from
smaller non-myelinated axons (Fig. 7A). During EAE,
both N1 and N2 CAP amplitudes were decreased to
nearly 50% of normal (P< 0.001; Fig. 7A–C). We report
significantly increased N1 and N2 CAP amplitudes in
GA-treated EAE CC compared with vehicle-treated EAE
CC (P< 0.001; Fig. 7A–C). This indicates that GA is
neuroprotective of both myelinated and non-myelinated
callosal axons. Given our immunohistochemical findings,
these functional improvements may be due to a combina-
tion of reduced axon loss, increased functional myelina-
tion, and reduced axon damage.
GA-Induced Improvement of Callosal Conduction
During EAE is Associated with Decreased Callosal
Inflammation and Enhanced Callosal Axon
Myelination
Detailed analysis of CC inflammation and myelina-
tion was performed in electrophysiologically recorded
Fig. 5. Therapeutic GA reduces axon damage and demyelination in spinal
cords of EAE mice. Consecutive thoracic spinal cord sections from nor-
mal controls, vehicle-treated EAE, and GA-treated EAE PLP_EGFP
mice euthanized on day 36 (Fig. 1B experiment, in which treatment was
initiated on day 21 at peak EAE) were immunostained with NF200
(green), MBP (red), and DAPI (blue; A) or NF200 (green), b-APP
(red), and DAPI (blue; C). The ventral column (VC; see Fig. 3A, dashed
boxes) was imaged at 340. Axons from the normal group revealed robust
NF200 and MBP immunostaining, with the majority of axons showing
red myelin around green axons. No APP1 axons were visible. In con-
trast, vehicle-treated EAE sections had decreased myelin and axonal stain-
ing, significantly fewer myelinated axons, and significantly more APP1
axons. A significant recovery in the number of axons and loss of APP1
axons was observed in GA-treated EAE mice. *P< 0.05, **P< 0.001, 1
3 4 ANOVA; n5 6 mice/group (B,D). [Color figure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
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post-fixed and non-recorded formalin-fixed brain slices
from mice in which GA therapy was initiated at EAE day
15 (Fig. 2A). Similar to previous studies (Crawford et al.,
2010; Mangiardi et al., 2011; Moore et al., 2013), micro-
glia and T cell-infiltrating lesions in CC of vehicle-treated
EAE animals were observed (Fig. 8A,C,D). Activation of
resident microglia in the CNS and lymphocytic infiltra-
tion into the CNS is pathological and characteristic of
EAE (Mangiardi et al., 2011). We report a significant,
approximately four-fold reduction of both CD451 acti-
vated microglia (Fig. 8B,C) and CD31 T cell infiltrates
(Fig. 8B,D) in the CC of GA-treated mice. Whereas the
vehicle-treated EAE group displayed a decrease in
PLP_EGFP1 OLs in delineated CC (Fig. 8A,E), GA-
treated EAE CC displayed a non-significant increase in
these cells (Fig. 8B,E).
MBP staining intensity analysis revealed a significant
recovery of callosal myelination in GA-treated EAE mice
compared with vehicle-treated EAE mice (Fig. 9A,D).
To test the hypothesis that improved myelination effects
are attributable to global changes in the OL cell line, we
examined OL cell line markers in the CC. CC11 mature
OLs were reduced in vehicle-treated EAE CC compared
with normal mice. GA increased mature OL numbers in
EAE mice (Fig. 9B,E). Similar to results in PLP_EGFP1
cells, olig21 OL lineage cells were reduced in vehicle-
treated EAE animals, with a non-significant trend toward
an increase in GA-treated EAE mice (Fig. 9C,F). Given
these results, increased myelination in the CC of thera-
peutic GA-treated EAE mice may be attributable to
enhanced survival and/or differentiation of mature
myelin-forming OLs. Overall, these results suggest that
therapeutic GA decreases infiltrating cell numbers in the
CC, providing an opportunity for recovery from inflam-
matory demyelination.
Therapeutic GA Normalizes EAE-Induced
Disorganization of Nodal Proteins in Callosal
Axons
To assess the extent of GA-induced conduction
recovery in callosal axons, nodal architecture was
Fig. 6. Therapeutic GA increases PLP_EGFP fluorescence in brain
sections of EAE mice. Consecutive PLP_EGFP1 (green) coronal brain
sections corresponding approximately to plates 29–48 in the atlas of
Franklin and Paxinos (2001) from the Figure 1B experiment were
stained with DAPI (red) and imaged at 32. Vehicle-treated EAE
mice show decreased PLP_EGFP fluorescence, especially in CC and
cortical layers, indicated as dashed boxes and asterisks (A). In addition,
callosal sections showed many perivascular infiltrating lesions with
increased DAPI1 nuclei (C, dashed boxes). In contrast, GA-treated
EAE mice showed increased PLP_EGFP fluorescence and fewer infil-
trating lesions (B,D). [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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visualized using the paranodal marker Caspr and the
nodal sodium channel marker Nav1.6. Reorganization
of nodal and perinodal axonal constituents precedes
remyelination, and Nav channel aggregation is an initial
step in the repair process (Coman et al., 2006). Patho-
logical rearrangement of axon ion channels away from
typical nodal architecture disrupts normal saltatory action
potential conduction, is associated with EAE, and may
contribute to clinical deficit (Arroyo et al., 2001; Black
et al., 2002; Crawford et al., 2010b). We report signifi-
cantly fewer Caspr1 nodes of Ranvier in the CC of
vehicle-treated EAE mice compared with GA-treated
EAE mice (from Fig. 2A; Fig. 10A,B). Although nodes
of Ranvier are one indicator of axonal integrity, proper
saltatory conduction requires colocalization with
voltage-gated sodium channels. We observed that the
voltage-gated sodium channel Nav1.6 colocalized more
frequently with Caspr1 nodes in the GA-treated condi-
tion (Fig. 10A,C). These results suggest that therapeutic
GA treatment preserves the proper axon nodal architec-
ture needed for effective callosal conduction and that
this change may mediate observed functional improve-
ments in CC axonal conduction.
DISCUSSION
Recent research has shed light on the immunomodulatory
properties that afford GA its disease-modifying efficacy
(Aharoni et al., 2010; Kala et al., 2011). However, little
was known about the functional outcomes of GA-
conferred immunomodulation and neuroprotection in
chronic EAE, the most widely accepted animal model of
progressive MS. In the current study, we mirrored a typi-
cal therapeutic MS treatment paradigm by initiating treat-
ment amidst active chronic clinical disease and studied
clinically relevant parameters, including brain pathology
Fig. 7. Therapeutic GA mitigates EAE-induced impairment in callosal
conduction. A: Callosal lesions and demyelination during chronic
EAE cause measurable conduction deficits. CAP responses were
recorded on EAE post-immunization day 36 from coronal slices con-
taining midline-crossing segments of the CC overlying the mid-dorsal
hippocampus (Fig. 1A experiment). Typical CC CAP from normal
(black), vehicle-treated EAE (red), and GA-treated EAE (blue) brains
were evoked at a stimulus of 4 mA. N1 (fast conducting, myelinated
component) and N2 (slow conducting, mostly non-myelinated com-
ponent) CAP amplitudes decreased in the vehicle-treated EAE group.
Treatment with GA during EAE brought CAP amplitudes closer to
those of the normal group by improving the EAE-induced decreases
in N1 and N2 CAP amplitudes. Dashed line represents CAP beyond
the stimulus artifact. B,C: Quantification of N1 and N2 CAP ampli-
tudes from brain slices of normal, vehicle-treated EAE, and GA-
treated EAE groups was performed. CAP amplitudes at 2–4 mA cur-
rent stimulation were compared. **P< 0.001, ANOVA, Bonferroni’s
multiple comparison post-test; n5 6 mice/group. [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.
com.]
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and functional correlates. More specifically, we studied
the behavioral, physiological, and cellular sequelae of
vehicle-treated vs. GA-treated EAE mice to understand
how the drug’s immunological and neuroprotective prop-
erties may modify late disease course. We sought to eluci-
date the distinct functional efficacy of the drug at different
phases of clinically evident disease (i.e., onset to peak),
both to increase our understanding of demyelinating dis-
ease progression and to optimize therapy. Like chronic
and secondary progressive MS, active EAE in C57BL/6
mice is characterized by chronic inflammatory demyeli-
nating lesions in the spinal cord that contribute to sensori-
motor deficit, measured with a standard EAE scoring
system that resembles the motor components of the
Kurtzke EDSS used for MS patients (Mangiardi et al.,
2011). In a recent trial studying treatment of RRMS, the
most common initial MS subtype, patients who received
GA treatment three times per week experienced a
reduced risk of EDSS disability progression compared
with placebo (Khan et al., 2005). Compared with the
Fig. 8. Therapeutic GA decreases EAE-induced callosal inflammation
and demyelination. Representative PLP_EGFP brain sections containing
CC from vehicle-treated EAE and GA-treated EAE mice (Ai and Bi;
Fig. 2A experiment; 310) were costained with CD45 (red) and DAPI
(blue). Dashed boxes denote areas of the spinal cord imaged at 340
(CD45, A,Bii; CD3, A,Biii). Green channel in Aii and Aiii was removed
to show CD451 and CD31 cells clearly. Vehicle-treated EAE spinal
cord had multifocal to coalescing infiltrates in the leptomeninges com-
pared with normal controls, where no inflammatory nuclei were
observed (Ai). GA treatment during EAE induced a decrease in DAPI1
and CD451 cell infiltrates and increased PLP_EGFP fluorescence in the
cortical layers and CC (Bi). Numbers of CD451 (C), CD31 (D), and
PLP_EGFP1 cells (E) per 400 mm2 within the delineated CC were
quantified. An increase was seen in vehicle-treated EAE mice but not in
GA-treated EAE mice, compared with normal controls. Data are repre-
sentative of experiments repeated in their entirety on another set of EAE
mice. **P< 0.001, ANOVA; n5 6–8 mice/group. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Fig. 9. Therapeutic GA during EAE increases myelin density and oli-
godendrocyte numbers. A,D: Formalin-fixed brain sections from
mice euthanized at post-immunization day 40 (Fig. 2A experiment)
were immunostained with MBP (red) and DAPI (blue) and imaged at
310. Vehicle-treated EAE mice had reduced MBP immunoreactivity
compared with normal controls. GA-treated EAE mice showed
increased MBP staining compared with vehicle-treated EAE mice.
Quantification was performed by delineating the CC as shown by
dotted lines in the normal panel. Myelin intensity is presented as per-
centage of normal (*P< 0.05; **P< 0.001 ANOVA, Bonferroni’s
multiple comparison post-test; n5 8–10 mice/group. B,E: To investi-
gate the potential role of OLs in GA treatment-induced preservation
of myelin, brain sections from PLP_EGFP mice were colabeled with
DAPI (blue) and mature OL marker APC/CC1 (red) and imaged at
340 (dashed boxes). Quantification of the number of normalized
CC11 cells per 400 mm2 indicated a decrease in vehicle-treated EAE
mice compared with normal controls. GA treatment caused a signifi-
cant increase in mature OLs compared with vehicle-treated EAE
mice. *P <0.05, **P< 0.001, ANOVA, Bonferroni’s multiple-
comparisons post-test; n5 8–10 mice/group. C,F: Consecutive sec-
tions from normal, vehicle-treated EAE, and GA-treated EAE groups
were immunostained with another OL marker (olig2, red) and DAPI
(blue) and imaged at 340. Quantification of the number of normal-
ized olig21 cells per 400 mm2 indicated a decrease in vehicle-treated
EAE mice compared with normal controls. GA treatment caused a
non-significant increase in olig21 cells compared with vehicle-treated
EAE mice. *P< 0.05, **P< 0.001, ANOVA, Bonferroni’s multiple-
comparisons post-test; n5 8–10 mice/group. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.
com.]
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discrete EAE clinical scale, in which an experimenter
scores the animal’s level of weakness or paralysis based on
an a priori scale, rotorod testing is a quantitative, more
replicable measure of motor function. Its advantages
include finer discrimination of motor deficit during early
EAE, although it is comparable to the EAE clinical scale
for assessing motor deficit in advanced disease. Its use in
EAE animals is well-characterized, and latency to fall
from the rotorod is inversely correlated with EAE scores
(Jones et al., 2008). Here, for the first time, we report sig-
nificantly improved rotorod motor performance and
amelioration of clinical scores in EAE mice treated with
therapeutic GA. In addition, we examined pathological
markers in the spinal cord to ascertain the mechanism of
therapeutic GA-mediated motor improvement during
EAE. GA treatment was protective against demyelination
in the spinal cord dorsal column. Indeed, reduction in
demyelinating inflammatory lesions and preservation of
axonal integrity in the spinal cord are major targets of
therapy for MS (Mangiardi et al., 2011).
In the present study, GA treatment during mid- to
late EAE was associated with reduced inflammatory infil-
tration and axon damage. These results confirm earlier
findings that both prophylactic and therapeutic GA treat-
ment regimens reduce spinal cord pathology and myelin
damage in EAE (Aharoni et al., 2008). Increased preva-
lence of intact axons and reduced loss of spinal cord
motor neurons were also observed in GA-treated EAE
mice, evidence that GA exerts neuroprotective effects in
the spinal cord that mediate clinical improvement (Ahar-
oni et al., 2011). Similar results were found in RRMS
patients receiving GA treatment, with reduced spinal cord
atrophy compared with interferon-b treatment (Shipova
et al., 2009) and reduced microglial activation (Ratchford
et al., 2012). In vitro, GA was found to promote brain-
derived neurotrophic factor and insulin-like growth factor
1 secretion from microglia (Qian et al., 2013) while
increasing the secretion of anti-inflammatory cytokine
interleukin (IL)-10 and decreasing the proinflammatory
cytokine tumor necrosis factor (TNF)-a (Pul et al.,
2011). To further characterize the extent of GA-
conferred CNS neuroprotection, we expanded the scope
of our study rostrally to the CC.
The CC, one of the largest CNS white matter tracts,
is an interhemispheric commissure that subserves cogni-
tive and sensorimotor functions and is subject to demyeli-
nating inflammatory lesions in EAE/MS (Boroojerdi
et al., 1998; Mangiardi et al., 2011). Here we report
increased OL cellularity and myelination in the CC with
therapeutic GA treatment initiated during mid to late
EAE. Axonal injury underlies clinical deficit in MS, and
topographic redistribution of ion channels away from typ-
ical nodal sites may underlie axon dysfunction in the set-
ting of axonal injury. In EAE, the pathologic
redistribution of voltage-gated sodium channels 1.2 and
1.6 on the axon was reported by Waxman (2008). We
found preserved CC nodal architecture in GA-treated
EAE mice with colocalization of sodium channels with
Fig. 10. Therapeutic GA treatment limits EAE-induced disorganization
of nodal proteins in callosal axons. A: Brain sections (from Fig. 2A
experiment) were immunostained with nodal proteins Caspr (red) and
Nav1.6 (green) and imaged at 100 3 magnification. A decrease in Caspr
and Nav1.6 staining occurred in the CC of vehicle-treated EAE mice.
In addition, extensive regions of axons were immunostained, and we
found Nav1.6 not confined between Caspr pairs. GA-treated EAE cal-
losal axons contained Caspr pairs (arrows) with Nav1.6, similar to normal
control groups. B,C: Quantification of Caspr protein pairs alone and
Caspr protein pair encompassing Nav1.6 protein shows a decrease in
vehicle-treated EAE callosal axons compared with normal and GA-
treated EAE mice. *P< 0.05, **P< 0.001, ANOVA, Bonferroni’s mul-
tiple comparison post-test; n5 8–10 mice/group. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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nodes of Ranvier, although this arrangement was patho-
logically disrupted in vehicle-treated EAE mice. The neu-
roprotective benefits of therapeutic GA treatment were
functionally beneficial, inasmuch as we observed
increased myelinated and non-myelinated CAP ampli-
tudes in GA-treated EAE mice. Thus, therapeutic GA
treatment results in functional improvement that is meas-
urable in vivo.
Our data point to a clear neuroprotective and/or
neural repair benefit of GA treatment in EAE, as seen in
clinical and physiological manifestations. Although a
greater response was seen with GA treatment initiated
earlier in disease, a significant suppressive effect on disease
progression was observed even during late chronic dis-
ease. Here, we show that GA reverses or ameliorates
chronic EAE disease burden in mice when treatment is
initiated at mid or late disease time points. Specifically, an
8 day GA treatment regimen initiated mid-EAE disease
(EAE post-induction day 16) resulted in decreased EAE
clinical scores, with animals improving from severe motor
disability to only mild tail weakness. When GA treatment
was started later in disease (EAE post-induction day 21),
animals displayed a significant, albeit less dramatic, reduc-
tion in disease burden. These findings demonstrate that
GA treatment significantly reduces disease even when
administered late in the disease course, and, importantly,
the data are indicative of a temporal window within the
disease course during which GA treatment is most effica-
cious. Additionally, the clinical benefits of GA on EAE
disease persisted even after the cessation of therapy. Our
results mirror those observed in long-term monitoring of
GA efficacy in EAE (mice and monkeys; Sela, 1999; Sela
and Teitelbaum, 2001; Teitelbaum et al., 2004). Clinical
evidence from patients with RRMS supports the neuro-
protective effects of GA. GA treatment reduced the pro-
portion of new T1 hypointense lesions transforming to
permanent black holes (Filippi et al., 2001). Black holes
are indicative of severe tissue damage and may be consid-
ered markers of irreversible axonal loss (Filippi et al.,
2001). In addition, in another phase III placebo-
controlled trial in patients with clinically isolated syn-
drome, GA treatment was associated with improved neu-
roaxonal integrity in a subgroup analysis of 34 patients
(Comi et al., 2009). A GA treatment trial in progressive
MS patients failed to demonstrate a treatment effect
(Wolinsky et al., 2007), but a clinincal trial showed that,
in MS patients with a mean disease duration of 22 years,
administration of GA for up to 15 years reduced relapse
rates and decreased disability progression and transition to
secondary progressive MS (Ford et al., 2010). Future
studies will seek to determine the cellular and molecular
nature of the disease stage that promotes response to ther-
apy. Furthermore, additional in vitro and in vivo studies
are warranted to determine the precise mechanism by
which GA-mediated immunomodulation promotes
remyelination and prevents axonal injury. Existing studies
point to an immunomodulatory effect of GA on antigen-
presenting cells and a shift in T cell populations including
Th1 to Th2 (Liblau, 2009). OL biology is another likely
target of GA therapy, both directly through growth fac-
tors and indirectly through an altered inflammatory envi-
ronment (Skihar et al., 2009). It is likely that GA
promotes a broad cascade of cellular and molecular events
across a diverse population of cells that alters the inflam-
matory milieu of MS/EAE, culminating in disease-
modifying effects.
ACKNOWLEDGMENTS
L.H. is an employee of Teva Pharmaceutical Industries
(Israel).
REFERENCES
Aharoni R, Arnon R, Eilam R. 2005. Neurogenesis and neuroprotection
induced by peripheral immunomodulatory treatment of experimental
autoimmune encephalomyelitis. J Neurosci 25:8217–8228.
Aharoni R, Herschkovitz A, Eilam R, Blumberg-Hazan M, Sela M,
Bruck W, Arnon R. 2008. Demyelination arrest and remyelination
induced by glatiramer acetate treatment of experimental autoimmune
encephalomyelitis. Proc Natl Acad Sci U S A 105:11358–11363.
Aharoni R, Eilam R, Stock A, Vainshtein A, Shezen E, Gal H,
Friedman N, Arnon R. 2010. Glatiramer acetate reduces Th-17 inflam-
mation and induces regulatory T-cells in the CNS of mice with
relapsing-remitting or chronic EAE. J Neuroimmunol 225:100–111.
Aharoni R, Vainshtein A, Stock A, Eilam R, From R, Shinder V, Arnon
R. 2011. Distinct pathological patterns in relapsing-remitting and
chronic models of experimental autoimmune enchephalomyelitis and
the neuroprotective effect of glatiramer acetate. J Autoimmunity 37:
228–241.
Arnon R, Sela M. 2003. Immunomodulation by the copolymer glatir-
amer acetate. J Mol Recognit 16:412–421.
Arroyo EJ, Xu T, Poliak S, Watson M, Peles E, Scherer SS. 2001. Inter-
nodal specializations of myelinated axons in the central nervous system.
Cell Tissue Res 305:53–66.
Audoin B, Ibarrola D, Malikova I, Soulier E, Confort-Gouny S, Duong
MV, Reuter F, Viout P, Ali-Cherif A, Cozzone PJ, Pelletier J, Ranjeva
JP. 2007. Onset and underpinnings of white matter atrophy at the very
early stage of multiple sclerosis: a two-year longitudinal MRI/MRSI
study of corpus callosum. Mult Scler 13:41–51.
Begum-Haque S, Christy M, Wang Y, Kasper E, Ochoa-Reparaz J,
Smith JY, Haque A, Kasper LH. 2013. Glatiramer acetate biases dendri-
tic cells towards an anti-inflammatory phenotype by modulating OPN,
IL-17, and RORgt responses and by increasing IL-10 production in
experimental allergic encephalomyelitis. J Neuroimmunol 254:117–124.
Black JA, Renganathan M, Waxman SG. 2002. Sodium channel
Na(v)1.6 is expressed along nonmyelinated axons and it contributes to
conduction. Brain Res Mol Brain Res 105:19–28.
Bloom JS, Hynd GW. 2005. The role of the corpus callosum in interhe-
mispheric transfer of information: excitation or inhibition? Neuropsy-
chol Rev 15:59–71.
Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ. 2003. Intracortical
multiple sclerosis lesions are not associated with increased lymphocyte
infiltration. Mult Scler 9:323–331.
Boroojerdi B, Hungs M, Mull M, Topper R, Noth J. 1998. Interhemi-
spheric inhibition in patients with multiple sclerosis. Electroencephalogr
Clin Neurophysiol 109:230–237.
Coman I, Aigrot MS, Seilhean D, Reynolds R, Girault JA, Zalc B,
Lubetzki C. 2006. Nodal, paranodal and juxtaparanodal axonal proteins
during demyelination and remyelination in multiple sclerosis. Brain
129:3186–3195.
Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A,
Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S,
Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P,
1634 Moore et al.
Journal of Neuroscience Research
Wynn D, Young C, Filippi M. 2009. Effect of glatiramer acetate on
conversion to clinically definite multiple sclerosis in patients with clini-
cally isolated syndrome (PreCISe study): a randomised, double-blind,
placebo-controlled trial. Lancet 374:1503–1511.
Crawford DK, Mangiardi M, Tiwari-Woodruff SK. 2009a. Assaying the
functional effects of demyelination and remyelination: revisiting field
potential recordings. J Neurosci Methods 182:25–33.
Crawford DK, Mangiardi M, Xia X, Lopez-Valdes HE, Tiwari-
Woodruff SK. 2009b. Functional recovery of callosal axons following
demyelination: a critical window. Neuroscience 164:1407–1421.
Crawford DK, Mangiardi M, Song B, Patel R, Du S, Sofroniew MV,
Voskuhl RR, Tiwari-Woodruff SK. 2010. Oestrogen receptor {beta}
ligand: a novel treatment to enhance endogenous functional remyelina-
tion. Brain 133:2999–3016.
Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. 2000. Glatir-
amer acetate (Copaxone) induces degenerate, Th2-polarized immune
responses in patients with multiple sclerosis. J Clin Invest 105:967–976.
Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G.
2001. Glatiramer acetate reduces the proportion of new MS lesions
evolving into “black holes.” Neurology 57:731–733.
Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R,
Luzzio C, Myers L, Panitch H, Preiningerova J, Pruitt A, Rose J, Rus
H, Wolinsky J. 2010. Continuous long-term immunomodulatory ther-
apy in relapsing multiple sclerosis: results from the 15-year analysis of
the US prospective open-label study of glatiramer acetate. Mult Scler
16:342–350.
Gilgun-Sherki Y, Panet H, Holdengreber V, Mosberg-Galili R, Offen
D. 2003. Axonal damage is reduced following glatiramer acetate treat-
ment in C57/bl mice with chronic-induced experimental autoimmune
encephalomyelitis. Neurosci Res 47:201–207.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP,
Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP,
Wolinsky JS. 2001. Copolymer 1 reduces relapse rate and improves dis-
ability in relapsing–remitting multiple sclerosis: results of a phase III mul-
ticenter, double-blind, placebo-controlled trial. Neurology 57:S16–S24.
Jones MV, Nguyen TT, Deboy CA, Griffin JW, Whartenby KA, Kerr
DA, Calabresi PA. 2008. Behavioral and pathological outcomes in
MOG 35–55 experimental autoimmune encephalomyelitis. J Neuroim-
munol 199:83–93.
Kala M, Miravalle A, Vollmer T. 2011. Recent insights into the mecha-
nism of action of glatiramer acetate. J Neuroimmunol 235:9–17.
Khan O, Shen Y, Caon C, Bao F, Ching W, Reznar M, Buccheister A,
Hu J, Latif Z, Tselis A, Lisak R. 2005. Axonal metabolic recovery and
potential neuroprotective effect of glatiramer acetate in relapsing–remit-
ting multiple sclerosis. Mult Scler 11:646–651.
Kornek B, Lassmann H. 2003. Neuropathology of multiple sclerosis: new
concepts. Brain Res Bull 61:321–326.
Kumar S, Patel R, Moore S, Crawford DK, Suwanna N, Mangiardi M,
Tiwari-Woodruff SK. 2013. Estrogen receptor beta ligand therapy acti-
vates PI3K/Akt/mTOR signaling in oligodendrocytes and promotes
remyelination in a mouse model of multiple sclerosis. Neurobiol Dis
56:131–144.
Liblau R. 2009. Glatiramer acetate for the treatment of multiple sclerosis:
evidence for a dual anti-inflammatory and neuroprotective role. J Neu-
rol Sci 287:S17–S23.
MacKenzie-Graham A, Tiwari-Woodruff SK, Sharma G, Aguilar C, Vo
KT, Strickland LV, Morales L, Fubara B, Martin M, Jacobs RE,
Johnson GA, Toga AW, Voskuhl RR. 2009. Purkinje cell loss in
experimental autoimmune encephalomyelitis. Neuroimage 48:637–651.
Mallon BS, Shick HE, Kidd GJ, Macklin WB. 2002. Proteolipid pro-
moter activity distinguishes two populations of NG2-positive cells
throughout neonatal cortical development. J Neurosci 22:876–885.
Mangiardi M, Crawford DK, Xia X, Du S, Simon-Freeman R, Voskuhl
RR, Tiwari-Woodruff SK. 2011. An animal model of cortical and cal-
losal pathology in multiple sclerosis. Brain Pathol 21:263–278.
Moore S, Khalaj AJ, Yoon J, Patel R, Hannsun G, Yoo T, Sasidhar M,
Martinez-Torres L, Hayardeny L, Tiwari-Woodruff SK. 2013. Thera-
peutic laquinimod treatment decreases inflammation, initiates axon
remyelination, and improves motor deficit in a mouse model of multi-
ple sclerosis. Brain Behav 3:664–682.
Morgen K, Sammer G, Courtney SM, Wolters T, Melchior H, Blecker
CR, Oschmann P, Kaps M, Vaitl D. 2006. Evidence for a direct associ-
ation between cortical atrophy and cognitive impairment in relapsing–
remitting MS. Neuroimage 30:891–898.
Niepel G, Tench Ch R, Morgan PS, Evangelou N, Auer DP,
Constantinescu CS. 2006. Deep gray matter and fatigue in MS: a T1
relaxation time study. J Neurol 253:896–902.
Ozturk A, Smith SA, Gordon-Lipkin EM, Harrison DM, Shiee N, Pham
DL, Caffo BS, Calabresi PA, Reich DS. 2010. MRI of the corpus cal-
losum in multiple sclerosis: association with disability. Mult Scler 16:
166–177.
Patel R, Moore S, Crawford DK, Hannsun G, Sasidhar MV, Tan K,
Molaie D, Tiwari-Woodruff SK. 2013. Attenuation of corpus callosum
axon myelination and remyelination in the absence of circulating sex
hormones. Brain pathology 23:462–475.
Pul R, Moharregh-Khiabani D, Skuljec J, Skripuletz T, Garde N, Voss
EV, Stangel M. 2011. Glatiramer acetate modulates TNF-alpha and IL-
10 secretion in microglia and promotes their phagocytic activity. J Neu-
roimmune Pharmacol 6:381–388.
Qian S, Tang Y, Cheng L, Sun X, Tian J, Zhou C. 2013. Interaction of
copolymer-1-activated T cells and microglia in retinal ganglion cell
protection. Clin Exp Ophthalmol 41:881–890.
Ratchford JN, Endres CJ, Hammoud DA, Pomper MG, Shiee N, McGready
J, Pham DL, Calabresi PA. 2012. Decreased microglial activation in MS
patients treated with glatiramer acetate. J Neurol 259:1199–1205.
Schrempf W, Ziemssen T. 2007. Glatiramer acetate: mechanisms of
action in multiple sclerosis. Autoimmun Rev 6:469–475.
Scott LJ. 2013. Glatiramer acetate: a review of its use in patients with
relapsing–remitting multiple sclerosis and in delaying the onset of clini-
cally definite multiple sclerosis. CNS Drugs 27:971–988.
Sela M. 1999. The concept of specific immune treatment against autoim-
mune diseases. Int Rev Immunol 18:201–216.
Sela M, Teitelbaum D. 2001. Glatiramer acetate in the treatment of mul-
tiple sclerosis. Expert Opin Pharmacother 2:1149–1165.
Shipova EG, Spirin NN, Kasatkin DS, Shumakov EI, Stepanov IO.
2009. State of the cervical section of the spinal cord in patients with
remitting multiple sclerosis during immunomodulatory treatment. Neu-
rosci Behav Physiol 39:47–51.
Skihar V, Silva C, Chojnacki A, Doring A, Stallcup WB, Weiss S, Yong
VW. 2009. Promoting oligodendrogenesis and myelin repair using the
multiple sclerosis medication glatiramer acetate. Proc Natl Acad Sci U
S A 106:17992–17997.
Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. 1971. Sup-
pression of experimental allergic encephalomyelitis by a synthetic poly-
peptide. Eur J Immunol 1:242–248.
Teitelbaum D, Aharoni R, Klinger E, Kreitman R, Raymond E, Malley
A, Shofti R, Sela M, Arnon R. 2004. Oral glatiramer acetate in experi-
mental autoimmune encephalomyelitis: clinical and immunological
studies. Ann N Y Acad Sci 1029:239–249.
Tiwari-Woodruff S, Morales LB, Lee R, Voskuhl RR. 2007. Differential
neuroprotective and anti inflammatory effects of estrogen receptor
(ER)alpha and (ER)beta ligand treatment. Proc Natl Acad Sci U S A
104:14813–14818.
Vollmer TL, Hadjimichael O, Preiningerova J, Ni W, Buenconsejo J.
2002. Disability and treatment patterns of multiple sclerosis patients in
Restoration of Motor Deficits by GA 1635
Journal of Neuroscience Research
United States: a comparison of veterans and nonveterans. J Rehabil Res
Dev 39:163–174.
Voskuhl RR, Peterson RS, Song B, Ao Y, Morales LB, Tiwari-
Woodruff S, Sofroniew MV. 2009. Reactive astrocytes form scar-like
perivascular barriers to leukocytes during adaptive immune inflamma-
tion of the CNS. J Neurosci 29:11511–11522.
Warlop NP, Fieremans E, Achten E, Debruyne J, Vingerhoets G. 2008.
Callosal function in MS patients with mild and severe callosal damage
as reflected by diffusion tensor imaging. Brain Res 1226:218–225.
Waxman SG. 2008. Mechanisms of disease: sodium channels and neuro-
protection in multiple sclerosis-current status. Nat Clin Pract Neurol 4:
159–169.
Weber MS, Prod’homme T, Youssef S, Dunn SE, Rundle CD, Lee L,
Patarroyo JC, Stuve O, Sobel RA, Steinman L, Zamvil SS. 2007. Type
II monocytes modulate T cell-mediated central nervous system autoim-
mune disease. Nat Med 13:935–943.
Weissert R. 2013. The immune pathogenesis of multiple sclerosis. J Neu-
roimmune Pharmacol 8:857–866.
Wolinsky JS, Narayana PA, O’Connor P, Coyle PK, Ford C, Johnson
K, Miller A, Pardo L, Kadosh S, Ladkani D. 2007. Glatiramer acetate
in primary progressive multiple sclerosis: results of a multinational,
multicenter, double-blind, placebo-controlled trial. Ann Neurol 61:
14–24.
1636 Moore et al.
Journal of Neuroscience Research
